Skip to Content

Merck Transfers Abbott Rights for Niaspan Outside the U.S.

DARMSTADT, Germany, July 18, 2007 – Merck KGaA announced today that it will give Abbott its rights for Niaspan®, a nicotinic acid product for lipid management.

Abbott, which acquired Kos Pharmaceuticals Inc. at the end of 2006 and is marketing Niaspan in the United States, will take over marketing and distributing the product in the former Merck territories. Merck entered into an agreement in 2002 with Kos of Miami, Florida, for marketing rights to Niaspan worldwide excluding North America and Japan.

Merck sales of Niaspan in 2006 were EUR 7.0 million.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to to register online, change your selection or discontinue this service.

Merck is a global pharmaceutical and chemical company with sales of EUR 6.3 billion in 2006, a history that began in 1668, and a future shaped by 35,091 employees in 62 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

Merck KGaA
Frankfurter Strasse 250 Head External Communications -2386 Darmstadt Site -7109
64293 Darmstadt Business and Financial Media -9591 / -7144 Fax +49 (0) 6151 72-3138
Hotline +49 (0) 6151 72-5000 Fax +49 (0) 6151 72-7707
Contact: Phyllis Carter Phone: +49 6151 72-7144

Posted: July 2007